10x Genomics, Inc. — Director's Dealing 2021

Jun 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-06-17

Reporting Person: STUELPNAGEL JOHN R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-17	Class A Common Stock	S	100	$190.97	Disposed	406516	Direct
2021-06-17	Class A Common Stock	S	100	$191.97	Disposed	406416	Direct
2021-06-17	Class A Common Stock	S	200	$195.295	Disposed	406216	Direct
2021-06-17	Class A Common Stock	S	400	$196.7463	Disposed	405816	Direct
2021-06-17	Class A Common Stock	S	500	$197.749	Disposed	405316	Direct
2021-06-17	Class A Common Stock	S	600	$199.3021	Disposed	404716	Direct
2021-06-17	Class A Common Stock	S	1700	$200.2309	Disposed	403016	Direct
2021-06-17	Class A Common Stock	S	1000	$201.0262	Disposed	402016	Direct
2021-06-17	Class A Common Stock	S	300	$202.1763	Disposed	401716	Direct
2021-06-17	Class A Common Stock	S	100	$203.42	Disposed	401616	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $194.99 to $195.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $196.36 to $197.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $197.48 to $198.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $198.72 to $199.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $199.725 to $200.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This transaction was executed in multiple trades at prices ranging from $200.74 to $201.32. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F8: This transaction was executed in multiple trades at prices ranging from $201.825 to $202.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.